Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation

摘要

Acute mixed-cell leukemia (AMAL) is defined as acute leukemia that possesses characteristics of both lymphoid and myeloid precursor cells. The prognosis of AMAL is poor, with an average OS of only 10 months in patients treated by chemotherapy alone, which is far shorter than that for patients with acute leukemias with single lineage origins. Although allogeneic hematopoietic SCT (allo-HSCT) can significantly prolong patient survival, intensified preconditioning is required to ensure long-term survival, which usually is not possible in elderly patients. However, in contrast to traditional allo-HSCT, related allogeneic hematopoietic stem cell micro-transplantation has been shown to be feasible and effective in elderly patients with AML